Literature DB >> 17040278

Heart rate variability in young women with polycystic ovary syndrome.

Aylin Yildirir1, Funda Aybar, Giray Kabakci, Hakan Yarali, Ali Oto.   

Abstract

BACKGROUND: Limited data are available related to the effects of sex hormones on cardiac autonomic function. Few studies investigated the heart rate variability (HRV) parameters during regular menstrual cycle or in postmenopausal women using hormone replacement therapy, but the results were contradictory. The aim of the study was to compare the characteristics of the autonomic innervation of the heart in polycystic ovary syndrome (PCOS) patients with regularly cycling controls.
METHODS: Thirty PCOS patients and 30 healthy regularly cycling controls were included in the study. Groups were compared with respect to age and various cardiovascular risk factors. Characteristics of autonomic innervation of the heart were evaluated with HRV. Power spectral analysis of HRV was performed to calculate the low frequency peak (LF 0.04-0.15 Hz), high-frequency peak (HF 0.15-0.40 Hz), LF in normalized unit (LF nu), HF in normalized unit (HF nu) and LF/HF ratio.
RESULTS: PCOS patients had adverse cardiovascular risk profile than controls. As the HRV parameters, PCOS patients had significantly higher LF nu (P = 0.005) and LF/HF ratio (P = 0.001) and significantly lower HF (P = 0.006) and HF nu (P < 0.001) compared to controls.
CONCLUSION: Autonomic innervation of the heart can be affected in PCOS with increased sympathetic and decreased parasympathetic components of HRV. As a result, sympathetic to parasympathetic ratio may increase in PCOS. This finding should be confirmed with larger studies also evaluating the clinical implications of altered HRV parameters.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17040278      PMCID: PMC6932634          DOI: 10.1111/j.1542-474X.2006.00122.x

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  38 in total

1.  Attenuation of heart-rate variability in postmenopausal women on progestin-containing hormone replacement therapy.

Authors:  M Christ; K Seyffart; M Wehling
Journal:  Lancet       Date:  1999-06-05       Impact factor: 79.321

2.  Climacteric vasomotor symptoms do not imply autonomic dysfunction.

Authors:  I Virtanen; P Polo-Kantola; R Erkkola; O Polo; E Ekholm
Journal:  Br J Obstet Gynaecol       Date:  1999-02

3.  Autonomic and cardiovascular function in postmenopausal women: the effects of estrogen versus combination therapy.

Authors:  Noha H Farag; Richard A Nelesen; Barbara L Parry; Jose S Loredo; Joel E Dimsdale; Paul J Mills
Journal:  Am J Obstet Gynecol       Date:  2002-05       Impact factor: 8.661

4.  Polycystic ovary syndrome is associated with endothelial dysfunction.

Authors:  G Paradisi; H O Steinberg; A Hempfling; J Cronin; G Hook; M K Shepard; A D Baron
Journal:  Circulation       Date:  2001-03-13       Impact factor: 29.690

5.  Effects of stroke localization on cardiac autonomic balance and sudden death.

Authors:  S L Tokgözoglu; M K Batur; M A Topçuoglu; O Saribas; S Kes; A Oto
Journal:  Stroke       Date:  1999-07       Impact factor: 7.914

6.  Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.

Authors: 
Journal:  Circulation       Date:  1996-03-01       Impact factor: 29.690

7.  Left ventricular function and autonomic nervous system balance during two different stages of the menstrual cycle.

Authors:  A J Fuenmayor; L Ramírez; A M Fuenmayor
Journal:  Int J Cardiol       Date:  2000-02-15       Impact factor: 4.164

8.  Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome.

Authors:  H Yarali; A Yildirir; F Aybar; G Kabakçi; O Bükülmez; E Akgül; A Oto
Journal:  Fertil Steril       Date:  2001-09       Impact factor: 7.329

Review 9.  Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women.

Authors:  E Carmina; R A Lobo
Journal:  J Clin Endocrinol Metab       Date:  1999-06       Impact factor: 5.958

10.  Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women.

Authors:  E Dahlgren; P O Janson; S Johansson; L Lapidus; A Odén
Journal:  Acta Obstet Gynecol Scand       Date:  1992-12       Impact factor: 3.636

View more
  28 in total

1.  Insulin resistance may be involved in relationship between cardiac autonomic dysfunction and polycystic ovary syndrome.

Authors:  Antonio Perciaccante; Alessandra Fiorentini
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-10       Impact factor: 1.468

2.  Ovarian hypertension: polycystic ovary syndrome.

Authors:  Rhonda Bentley-Lewis; Ellen Seely; Andrea Dunaif
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

Review 3.  Medical management of metabolic dysfunction in PCOS.

Authors:  Antoni J Duleba
Journal:  Steroids       Date:  2011-12-13       Impact factor: 2.668

Review 4.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

Review 5.  PCOS Forum: research in polycystic ovary syndrome today and tomorrow.

Authors:  Renato Pasquali; Elisabet Stener-Victorin; Bulent O Yildiz; Antoni J Duleba; Kathleen Hoeger; Helen Mason; Roy Homburg; Theresa Hickey; Steve Franks; Juha S Tapanainen; Adam Balen; David H Abbott; Evanthia Diamanti-Kandarakis; Richard S Legro
Journal:  Clin Endocrinol (Oxf)       Date:  2011-04       Impact factor: 3.478

6.  Heart Rate Changes in Electroacupuncture Treated Polycystic Ovary in Rats.

Authors:  Mukilan Ramadoss; Gunasekaran Ramanathan; Angelie Jessica Subbiah; Chidambaranathan Natrajan
Journal:  J Clin Diagn Res       Date:  2016-03-01

Review 7.  Developmental programming of cardiovascular disorders: focus on hypertension.

Authors:  Sheba M J MohanKumar; Andrew King; Andrew C Shin; Madhu P Sirivelu; P S MohanKumar; Gregory D Fink
Journal:  Rev Endocr Metab Disord       Date:  2007-08-01       Impact factor: 6.514

8.  Excess of nerve growth factor in the ovary causes a polycystic ovary-like syndrome in mice, which closely resembles both reproductive and metabolic aspects of the human syndrome.

Authors:  Jenny L Wilson; Weiyi Chen; Gregory A Dissen; Sergio R Ojeda; Michael A Cowley; Cecilia Garcia-Rudaz; Pablo J Enriori
Journal:  Endocrinology       Date:  2014-09-11       Impact factor: 4.736

9.  Regulation of Blood Pressure, Appetite, and Glucose by CNS Melanocortin System in Hyperandrogenemic Female SHR.

Authors:  Jussara M do Carmo; Alexandre A da Silva; Sydney P Moak; Haley J Houghton; Andrew Smith; John E Hall
Journal:  Am J Hypertens       Date:  2015-11-18       Impact factor: 2.689

Review 10.  Sex-Bias in Irritable Bowel Syndrome: Linking Steroids to the Gut-Brain Axis.

Authors:  Sik Yu So; Tor C Savidge
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-19       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.